Literature DB >> 22560791

Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation.

Marika Pane1, Maria Elena Lombardo, Paolo Alfieri, Adele D'Amico, Flaviana Bianco, Gessica Vasco, Giorgia Piccini, Maria Mallardi, Domenico M Romeo, Valeria Ricotti, Alessandra Ferlini, Francesca Gualandi, Stefano Vicari, Enrico Bertini, Angela Berardinelli, Eugenio Mercuri.   

Abstract

OBJECTIVES: To assess attention deficit hyperactivity disorder (ADHD) in boys affected by Duchenne muscular dystrophy (DMD) and to explore the relationship with cognitive abilities and genetic findings. STUDY
DESIGN: Boys with DMD (n = 103; 4-17 years of age, mean: 12.6) were assessed using a cognitive test (Wechsler scales). Assessment of ADHD was based on the Diagnostic Statistical Manual, Fourth Edition, Text Revision criteria and on the long version of the Conners Parents and Teachers Rating Scales.
RESULTS: ADHD was found in 33 of the 103 boys with DMD. Attention problems together with hyperactivity (17/33) or in isolation (15/33) were more frequent than hyperactivity alone, which was found in 1 patient. Intellectual disability (ID) was found in 27/103 (24.6%). Sixty-two of the 103 boys had no ID and no ADHD, 9 had ID but no ADHD, 14 had ADHD but no ID, and 18 had both. ADHD occurred more frequently in association with mutations predicted to affect Dp140 expression (exon 45-55) and in those with mutations predicted to affect all dystrophin product, including Dp71 (ie, those that have promoter region and specific first exon between exons 62 and 63 but were also relatively frequent).
CONCLUSIONS: Our results suggest that ADHD is a frequent feature in DMD. The risk of ADHD appears to be higher in patients carrying mutations predicted to affect dystrophin isoforms expressed in the brain and are known to be associated with higher risk of cognitive impairment.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22560791     DOI: 10.1016/j.jpeds.2012.03.020

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  41 in total

1.  Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies.

Authors:  Yingyin Liang; Songlin Chen; Jianzong Zhu; Xiangxue Zhou; Chen Yang; Lu Yao; Cheng Zhang
Journal:  Bosn J Basic Med Sci       Date:  2015-05-20       Impact factor: 3.363

Review 2.  Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.

Authors:  Rylie M Hightower; Matthew S Alexander
Journal:  Muscle Nerve       Date:  2017-09-22       Impact factor: 3.217

Review 3.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

4.  Autism spectrum disorders are prevalent among patients with dystrophinopathies.

Authors:  Haruo Fujino; Toshio Saito; Tsuyoshi Matsumura; Saki Shibata; Yuko Iwata; Harutoshi Fujimura; Osamu Imura
Journal:  Neurol Sci       Date:  2018-03-28       Impact factor: 3.307

Review 5.  Duchenne muscular dystrophy: current cell therapies.

Authors:  Dorota Sienkiewicz; Wojciech Kulak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Katarzyna Kawnik
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

6.  Neurobehavioral Concerns Among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Authors:  Kristin Caspers Conway; Katherine D Mathews; Pangaja Paramsothy; Joyce Oleszek; Christina Trout; Ying Zhang; Paul A Romitti
Journal:  J Dev Behav Pediatr       Date:  2015 Jul-Aug       Impact factor: 2.225

7.  In Vivo Evaluation of White Matter Abnormalities in Children with Duchenne Muscular Dystrophy Using DTI.

Authors:  V Preethish-Kumar; A Shah; M Kumar; M Ingalhalikar; K Polavarapu; M Afsar; J Rajeswaran; S Vengalil; S Nashi; P T Thomas; A Sadasivan; M Warrier; A Nalini; J Saini
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-02       Impact factor: 3.825

8.  Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system.

Authors:  Valeria Ricotti; Herbert Jägle; Maria Theodorou; Anthony T Moore; Francesco Muntoni; Dorothy A Thompson
Journal:  Eur J Hum Genet       Date:  2015-06-17       Impact factor: 4.246

Review 9.  Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; Mary K Colvin; Linda Cripe; Adrienne R Herron; Annie Kennedy; Kathi Kinnett; James Naprawa; Garey Noritz; James Poysky; Natalie Street; Christina J Trout; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-02       Impact factor: 44.182

Review 10.  Current and Emerging Therapies for Duchenne Muscular Dystrophy.

Authors:  Megan Crone; Jean K Mah
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.